What does CUSIP N62509117 represent in this 13F holders report?

CUSIP N62509117 is the security identifier for NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 used to aggregate holder disclosures.

How many institutions held NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 in Q2 2023?

18 institutional investors reported NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 for Q2 2023. Use the holders table for investor-level position and value details.

999 (NAMSW)

CUSIP: N62509117

Q2 2023 13F Holders as of 30 Jun 2023

Security type / class: Equity / *W EXP 99/99/999
Total 13F shares: 1,884,490
Total 13F value: $3,937,717
Share change: -352,417
SEC-reported price per share: $2.09
Number of holders: 18
Value change: -$730,847
Number of buys: 3
Number of sells: 5

Security key

N62509117

Report period

Q2 2023

Institutions

Top holders

NAMSW full security history Ownership snapshot Full 13F holder table NewAmsterdam Pharma Co N.V. SEC filings NewAmsterdam Pharma Co N.V. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

VIKING GLOBAL INVESTORS LP

Disclosed value leader

Frazier Life Sciences Man...

Comparable rows

14/15

Latest evidence

31 Mar 2023

13F Lead comparable stake: 3.3% 1 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VIKING GLOBAL INVESTORS LP leads the comparable SEC ownership view at 3.3%.

14 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VIKING GLOBAL INVESTORS LP's linked filing trail.

Comparable ownership Top 5

VIKING GLOBAL INVESTORS LP 3.3%

Medicxi Ventures Management (Jers... 1.7%

BVF INC/IL 1.3%

GMT CAPITAL CORP 0.92%

Parkman Healthcare Partners LLC 0.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
VIKING GLOBAL INVESTORS LP	13F Company 13F	3.3%	$52,629,293 3,915,870 shares	—	31 Mar 2023
Medicxi Ventures Management (Jersey) Ltd	13F Company 13F	1.7%	$26,520,000 2,000,000 shares	—	31 Mar 2023
BVF INC/IL	13F Company 13F	1.3%	$20,454,981 1,521,948 shares	—	31 Mar 2023
GMT CAPITAL CORP	13F Company 13F	0.92%	$14,371,188 1,083,800 shares	—	31 Mar 2023
Parkman Healthcare Partners LLC	13F Company 13F	0.1%	$1,524,900 115,000 shares	—	31 Mar 2023
MILLENNIUM MANAGEMENT LLC	13F Company 13F	0.05%	$748,000 55,633 shares	—	31 Mar 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

1,884,490

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q2 2023 value	Value change	Value Chg %